Biotech RadarJobs updated

COMPANY

xCures

HQ: Oakland, CA source · xcures.com ↗ · West Coast

Location: Oakland, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Bladder Cancer Oncology Pancreatic Cancer Small Bowel Cancer Colorectal Cancer Melanoma Non Small Cell Lung Cancer Thyroid Cancer Head and Neck Cancer Gastric Cancer Esophageal Cancer Cholangiocarcinoma Ovarian Cancer Hepatocellular Carcinoma Glioblastoma MAPK Gene Mutation KRAS Activating Mutation BRAF Gene Mutation NRAS Gene Mutation HRAS Gene Mutation MEK Mutation ERK Mutation Alpha-Thalassemia Beta-Thalassemia Amyloidosis Amyotrophic Lateral Sclerosis Creutzfeld-Jakob Disease Cystic Fibrosis Duchenne Muscular Dystrophy Early-Onset Alzheimer Disease Ehlers-Danlos Syndrome Huntington Disease Gaucher Disease GM1 Gangliosidosis Myasthenia Gravis Pompe Disease Sickle Cell Disease Transthyretin Amyloid Cardiomyopathy Rare Diseases DIPG

$46.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

  1. Raise Private equity round — Series B: $46M (total, as published), announced Jun 24, 2026. Source: company's own press page. source ↗
  2. Partnership Partnership / licensing announced Mar 5, 2026. Source: company's own press page. source ↗
  3. Trial start —: FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases source ↗
  4. Trial start —: xPedite: A Study to Expedite DIPG and DMG Research source ↗
  5. Trial start —: Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib source ↗
  6. Trial start —: Behavior, Environment And Treatments for Covid-19 source ↗
  7. Trial start —: A Patient-Centric Platform Trial for Precision Oncology source ↗

Funding

Raised: $46.0M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT04566393Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesNot listedAvailableNot listedNot listed
NCT06539169FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesNot listedUnknown status (ClinicalTrials.gov)Jun 10, 2024Jun 10, 2026 (estimated)
NCT06140719xPedite: A Study to Expedite DIPG and DMG ResearchNot listedRecruitingNov 1, 20232026-09 (estimated)
NCT03793088A Patient-Centric Platform Trial for Precision OncologyNot listedUnknown status (ClinicalTrials.gov)Feb 7, 20192024-01 (estimated)
NCT05052372Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving ErdafitinibNot listedTerminatedNov 21, 2021Dec 20, 2022 (actual)
NCT04321811Behavior, Environment And Treatments for Covid-19Not listedCompletedMar 21, 2020Feb 9, 2021 (actual)
Feedback